Actinium Pharmaceuticals (ATNM) Competitors $1.17 -0.06 (-4.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.20 +0.03 (+2.65%) As of 02/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends ATNM vs. ADCT, SGMT, PBYI, CHRS, SLDB, BMEA, TELO, MCRB, TIL, and KYTXShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include ADC Therapeutics (ADCT), Sagimet Biosciences (SGMT), Puma Biotechnology (PBYI), Coherus BioSciences (CHRS), Solid Biosciences (SLDB), Biomea Fusion (BMEA), Telomir Pharmaceuticals (TELO), Seres Therapeutics (MCRB), Instil Bio (TIL), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. ADC Therapeutics Sagimet Biosciences Puma Biotechnology Coherus BioSciences Solid Biosciences Biomea Fusion Telomir Pharmaceuticals Seres Therapeutics Instil Bio Kyverna Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership. Do analysts recommend ATNM or ADCT? Actinium Pharmaceuticals presently has a consensus target price of $7.40, suggesting a potential upside of 532.48%. ADC Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 389.30%. Given Actinium Pharmaceuticals' higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of ATNM or ADCT? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ATNM or ADCT more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% ADC Therapeutics -300.00%N/A -61.33% Does the MarketBeat Community prefer ATNM or ADCT? ADC Therapeutics received 53 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 67.44% of users gave ADC Therapeutics an outperform vote while only 38.46% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes538.46% Underperform Votes861.54% ADC TherapeuticsOutperform Votes5867.44% Underperform Votes2832.56% Does the media favor ATNM or ADCT? In the previous week, ADC Therapeutics had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for ADC Therapeutics and 0 mentions for Actinium Pharmaceuticals. ADC Therapeutics' average media sentiment score of 0.97 beat Actinium Pharmaceuticals' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Actinium Pharmaceuticals Neutral ADC Therapeutics Positive Which has better valuation & earnings, ATNM or ADCT? Actinium Pharmaceuticals has higher earnings, but lower revenue than ADC Therapeutics. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$80K456.30-$48.82M-$1.39-0.84ADC Therapeutics$69.56M2.27-$240.05M-$2.39-0.68 Which has more risk & volatility, ATNM or ADCT? Actinium Pharmaceuticals has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. SummaryADC Therapeutics beats Actinium Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$38.37M$7.07B$5.85B$20.34BDividend YieldN/A2.76%4.76%3.64%P/E RatioN/A2.5616.5128.66Price / Sales456.30304.55450.0215.49Price / CashN/A65.6738.0120.33Price / Book0.896.717.644.80Net Income-$48.82M$138.11M$3.18B$1.02B7 Day Performance1.74%-2.54%-1.95%-1.05%1 Month Performance-11.36%-2.00%-0.23%-1.09%1 Year PerformanceN/A-5.04%16.69%13.70% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.5353 of 5 stars$1.17-4.9%$7.40+532.5%N/A$38.37M$80,000.000.0030ADCTADC Therapeutics2.8839 of 5 stars$1.46-3.6%$8.00+449.8%-65.1%$140.68M$69.56M-0.61310Short Interest ↓SGMTSagimet Biosciences1.8145 of 5 stars$4.57-0.1%$23.00+403.6%-38.9%$140.13M$2M0.008PBYIPuma Biotechnology3.7611 of 5 stars$2.79+0.5%$7.00+150.5%-55.5%$136.71M$243.57M5.80200Upcoming EarningsNews CoverageCHRSCoherus BioSciences3.6629 of 5 stars$1.18+4.9%$5.38+357.4%-56.9%$136.17M$257.24M-14.69330SLDBSolid Biosciences4.081 of 5 stars$3.40+18.0%$15.30+350.1%-42.4%$135.29M$8.09M-1.11100Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeBMEABiomea Fusion3.3375 of 5 stars$3.73-0.5%$39.36+954.5%-77.4%$134.99MN/A-0.9350Positive NewsTELOTelomir Pharmaceuticals2.2926 of 5 stars$4.47+2.3%N/A-54.8%$132.91MN/A-7.701Analyst ForecastNews CoverageMCRBSeres Therapeutics3.9958 of 5 stars$0.78-0.6%$5.08+554.2%-23.5%$132.66M$126.33M-3.38330News CoverageTILInstil Bio2.9421 of 5 stars$20.28-2.6%$114.00+462.1%+88.3%$132.43MN/A-1.76410News CoverageKYTXKyverna Therapeutics1.1479 of 5 stars$3.03+0.8%$25.71+750.1%-89.9%$130.16M$7.03M0.0096 Related Companies and Tools Related Companies ADC Therapeutics Alternatives Sagimet Biosciences Alternatives Puma Biotechnology Alternatives Coherus BioSciences Alternatives Solid Biosciences Alternatives Biomea Fusion Alternatives Telomir Pharmaceuticals Alternatives Seres Therapeutics Alternatives Instil Bio Alternatives Kyverna Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ATNM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
